AbstrAct Alirocumab is a fully human monoclonal antibody to PCSK9. The ODYSSEY MONO study was the first alirocumab Phase III study to test a previously unused dose of 75 mg subcutaneously every 2 weeks in a population on no lipid-lowering therapy. A total of 103 patients were randomly assigned to alirocumab starting at 75 mg subcutaneously every 2 weeks or ezetimibe 10 mg per os every day with alirocumab dose uptitration at 12 weeks based on achieved LDL-cholesterol level at week 8 and followed to week 24. At the week-24 primary end point, the alirocumab intent-to-treat group showed a 47.2% (least square [LS] mean) reduction in LDL-cholesterol compared with a 15.6% (LS mean) reduction with ezetimibe (LS mean difference of 31.6%; p < 0.0001). Safety parameters and adverse events were similar between the two groups.
LDL-cholesterol (LDL-C) is considered to be a major modifiable risk factor for the development of atherosclerosis and cardiovascular disease (CVD) [1] , the leading cause of death worldwide [2] . LDL-C is identified as the primary target of cholesterol-lowering therapy by North American [3, 4] and European [5] guidelines. Statins are the recommended first-line therapy for lowering LDL-C. Despite LDL-C-lowering therapies, there are still many patients who cannot achieve a LDL-C level low enough to optimally prevent primary or recurrent cardiovascular (CV) events [6] . In addition, there is currently a greater recognition of the prevalence of heterozygous familial hypercholesterolemia as the most common genetic disorder in humans, and new data suggest an actual occurrence of approximately 1:200, suggesting a US adult population of 1 million and worldwide estimates of 14-34 million [7] . There is a need for additional lipid-lowering therapies (LLT) that can be used with a statin or instead of a statin for those who cannot tolerate statin therapy at any dose [8] .
PCSK9 was first reported to have a significant role in the regulation of LDL-C in 2003 [9, 10] . LDL receptors (LDLr) typically bind an LDL particle, become internalized and then return to the cell surface after releasing the LDL particle to a lysosome for degradation. This LDLr recycling is estimated to occur over 100 times per LDLr [11] . PCSK9 binds to the LDLr and prevents LDLr recycling by preventing release of the LDL particle, causing degradation of both the LDL particle and LDLr. Inhibiting PCSK9 causes increased LDLr numbers because of increased recycling and decreased destruction, with a resultant decrease in LDL-C. Several monoclonal antibodies (mAbs) to PCSK9 have now entered Phase III testing and promising Phase I and II results have been reported [12] .
Alirocumab (formerly SAR236553/REGN727) is a fully human mAb to PCSK9 being developed jointly by Sanofi (France) and Regeneron (NY, USA). Phase I and II studies have been completed and previously described [13] [14] [15] [16] . The Phase II studies utilized 150 mg of alirocumab as the most common dose and provided limited data in patients not receiving statin therapy. Computer modeling based on Phase II [18] .
clinicAl triAl report Roth & McKenney future science group data suggested that a 75-mg dose of alirocumab subcutaneously (sc.) every 2 weeks (Q2W) should yield an approximate 50% reduction in LDL-C as a monotherapy [17] . The first completed Phase III study, entitled ODYSSEY MONO, tested the new lower 75-mg dose of alirocumab sc. Q2W as a monotherapy versus ezetimibe 10 mg per os (po.) every day (q.d.) as a control [18] .
Study design
ODYSSEY MONO was a randomized, double-blind, double-dummy, active-controlled (ezetimibe), parallel-group study to investigate the efficacy and safety of alirocumab over 24 weeks in 100 patients with hypercholesterolemia on no LLT. Inclusion criteria included patients with an LDL-C between 100 mg/dl (≥2.6 mmol/l) and 190 mg/dl (<4.9 mmol/l; inclusive) and not on LLT. In addition, patients needed to have moderate CV risk defined as a 10-year risk of fatal CV events ≥1% and <5% based on the European Systematic Coronary Risk Estimation (SCORE) [19] . Key exclusion criteria were established coronary heart disease or coronary heart disease risk equivalents defined as manifestations of noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm and carotid artery disease), use of any LLT within 4 weeks or a fibrate within 6 weeks of the screening visit, fasting serum triglycerides >400 mg/dl (>4.52 mmol/l) during the screening period and systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening (week -2) or randomization (week 0) visits [18] . Institutional Review Boards or Ethics Boards approved the study protocol at all participating research sites. The study complied with the International Conference on Harmonization Good Clinical Practice Guidelines and all applicable local regulations. All patients provided written informed consent.
Patients were randomized in a 1:1 ratio to alirocumab 75 mg sc. Q2W plus ezetimibe placebo po. q.d. (alirocumab group) or alirocumab placebo sc. Q2W plus ezetimibe 10 mg po. q.d. (ezetimibe group). The alirocumab dosing was continued from week 0 through to week www.futuremedicine.com 24 unless the week-8 LDL-C was ≥100 mg/dl (≥2.5 mmol/l), in which case the alirocumab dose was to be increased to 150 mg sc. Q2W from week 12 to week 24 (last injection at week 22 in both cases). Due to an administrative error, blinded uptitration actually occurred if week-8 LDL-C was ≥70 mg/dl (≥1.8 mmol/l). Both doses of alirocumab were self-administered by autoinjector. Blood samples for multiple parameters were obtained at weeks 0, 4, 8, 12, 16, 24 and 32 (Figure 1) . The primary end point was the percentage change in LDL-C from baseline to week 24 and major secondary end points included the percentage change in LDL-C from baseline to week 12, the percentage change in ApoB, ApoA1, Lp(a), non-HDL-cholesterol (non-HDL-C), total cholesterol, HDL-C, triglycerides and HbA1c from baseline to weeks 12 and 24. Safety end points were adverse events (AEs; including adjudicated CV events), laboratory data, injection site reactions and vital signs assessed throughout the study. Other end points included serum alirocumab concentrations and antialirocumab antibodies also assessed throughout the study. Fifty-two patients were enrolled in the alirocumab group and 51 into the ezetimibe group at eight centers worldwide (USA, Belgium, Finland and The Netherlands). A total sample size of 90 patients (45 in each group) was calculated to have 95% power to detect a difference in mean percentage change in LDL-C of 20% with a 0.05 two-sided significance level assuming a common standard deviation of 25% and a 5% nonevaluable primary end point.
•
• Data analysis
The primary efficacy analysis population was the intent-to-treat (ITT) population, defined as the randomized population that actually received at least one dose or partial dose of investigational medicinal product (IMP) and had both the baseline and at least one subsequent LDL-C value. The ITT population included all patients and laboratory assessments regardless of whether the patient was on or off double-blind IMP or regardless of the timing of laboratory samples. The safety population consisted of the randomized population who actually received at least one dose or partial dose of IMP analyzed according to the treatment actually received. Safety analysis (AEs [including adjudicated CV events], laboratory parameters, injection site reactions and vital signs) was descriptive, based on the safety population. The safety analysis focused on the treatmentemergent AE (TEAE) period, defined as the time from the first double-blind dose of the IMP clinicAl triAl report Roth A total of 204 subjects were screened and 103 were randomized, 52 to the alirocumab group and 51 to the ezetimibe group. All 103 randomized subjects received study treatment (the safety population), but one patient from each treatment arm withdrew from treatment before any on treatment postrandomization LDL-C measurements were made (but continued in the study and had subsequent LDL-C levels obtained); the remaining 101 subjects constituted the mITT or 'on-treatment' population. Overall, 15 patients did not complete the study treatment period. The percentage of patients who discontinued the IMP during the study was similar in the alirocumab group (eight patients; 15.4%) and the ezetimibe group (seven patients; 13.7%). The percentage of patients who discontinued the IMP due to AEs was also comparable between the two treatment groups (five patients [9.6%] in the alirocumab group and four patients [7. 8%] in the ezetimibe group; Table 1 ).
Demographics and baseline lipid values were well balanced (Table 2 ). The protocol called for uptitration of the alirocumab dose at week 12 if LDL-C was ≥100 mg/dl at week 8, which was prompted by a blinded interactive voice responsive system. Instead, the interactive voice responsive system was incorrectly programmed to uptitrate subjects if LDL-C was ≥70 mg/dl. This discrepancy was not known until after study database lock. A total of 14 patients were uptitrated, and of these, only one patient had an LDL-C ≥100 mg/dl at week 8.
• lipid results
The LDL-C was reduced in both the ezetimibe and alirocumab groups by week 4; these reductions in LDL-C between the alirocumab and ezetimibe groups were statistically significant at weeks 12 and 24. Despite uptitration of 14 alirocumab patients at week 12 to 150 mg sc. Q2W, the LDL-C values observed at both weeks 12 and 24 were similar (Figure 2) . The primary end point -the percentage difference in least square (LS) mean LDL-C between the alirocumab group and the ezetimibe group at 24 weeks was -31.6% for the ITT population and -36.9% for the mITT population (p < 0.0001 for both ITT and mITT populations). LDL-C lowering in the ITT population with alirocumab was 47.2% and with ezetimibe was 15.6%. The LDL-C lowering with alirocumab was approximately 50%, as predicted for the 75-mg dose based on modeling of Phase II data, and the LDL-C lowering with ezetimibe was 17-20%, as reported in previous ezetimibe studies [20] . The changes in lipid values in the mITT or 'on-treatment' group were better than the ITT group because mITT only included those patients and visits where the study drug was taken and laboratory work was performed within the appropriate time window for the visits. There were also statistically significant differences between alirocumab and ezetimibe changes for ApoB, non-HDL-C and total cholesterol (Figure 3) . A hierarchical approach was used for analyzing the data, which resulted in statistical testing being stopped when Lp(a) did not prove statistically significant. Lp(a) was lowered 18% by alirocumab, consistent with what would be expected based on Phase II data, but was lowered 10% with ezetimibe, a result that was not expected and had not been previously reported. The cause of this decrease is unknown.
• Uptitrated versus non-uptitrated groups
Fourteen patients were uptitrated from 75 to 150 mg of alirocumab sc. Q2W at week 12 based on week 8 LDL-C being ≥70 mg/dL and continued this dose until week 22 (last injection); however, only one of these patients should have been uptitrated by the protocol. Thirtytwo patients were not uptitrated and received alirocumab 75 mg sc. Q2W from baseline to week 22 (last injection). Only the 46 patients who achieved a week-12 visit were included in the following analysis, including the 13 inappropriately uptitrated patients. Alirocumab blood levels were equivalent at week 12 prior to study drug injection but, at week 24, the uptitrated group showed approximately double the alirocumab blood level of the non-uptitrated group. The uptitrated group had a baseline LS mean LDL-C level of 153 mg/dl (3.95 mmol/l) versus 135 mg/dl (3.49 mmol/l) for the nonuptitrated group. LDL-C levels from baseline to week 24 can be seen in Figure 4 . To determine whether the nonprotocol uptitration of the 13 patients with LDL-C levels between 70 and 100 mg/dl affected the results, a recalculation of the primary end point excluding these 13 patients' data after week 12 was performed and did not yield a significantly different result (ezetimibe: -15.6% change in LDL-C; alirocumab: -44.3% change in LDL-C). In addition, the week-12 data for LDL-C before uptitration occurred showed a 19.6% decrease for ezetimibe and a 48.1% decrease for alirocumab; neither value is statistically different from the week-24 data with or without the 13 patients being inappropriately uptitrated.
• Safety
TEAEs were reported in 36 of 52 patients (69.2%) in the alirocumab group compared with 40 of 51 patients (78.4%) in the ezetimibe group (Table 3 ). The differences in the most frequently reported TEAEs in the alirocumab group versus the ezetimibe group were not considered clinically significant. Muscle disorders (myalgia and muscle spasms) occurred in a similar frequency within both treatment groups (3.8% in the alirocumab group and 3.9% in the ezetimibe group). Two treatmentemergent serious AEs were reported in two patients: pulmonary embolism in one patient of the alirocumab group and bone erosion in one patient of the ezetimibe group. Neither of the serious AEs was considered to be related to the IMPs by the investigator. Nine patients prematurely discontinued treatment due to a TEAE: five patients (9.6%) in the alirocumab group and four patients (7.8%) in the ezetimibe group. Six patients (11.5%) in the alirocumab group and five patients (9.8%) in the ezetimibe group had at least one allergic TEAE. One patient in the alirocumab group discontinued treatment permanently due to a potential allergic TEAE (flushing and other concomitant symptoms of fatigue, nausea and headache). (Table 4 ) and one ezetimibe patients at some visit during the study. All seven patients had elevated glucose (≥100 mg/dl [5.5 mmol/l]) or HbA1c levels (≥6.5%) at screening or baseline before receiving IMP and three of the six alirocumab patients had the diagnosis of diabetes mellitus at screening. There was no pattern of change in glucose or HbA1c from screening to week 24. Three patients in the alirocumab group treated with 75 mg Q2W had an LDL-C value <25 mg/dl (<0.65 mmol/l) and one had two consecutive LDL-C values <25 mg/dl (<0.65 mmol/l). No particular safety concern was observed in this patient. No patient had an LDL-C value <15 mg/dl (<0.39 mmol/l) at any time in the study. A total of four patients had a positive antidrug antibody (ADA) status at least once during the 24-week study period (Table 5 ). All had low ADA titers, which continued to decline to very low levels or become ADA negative from week 12 to the week-32 followup visit. There were no differences between the uptitrated and non-uptitrated groups. No safety concerns were observed in these patients; there were no neutralizing antibodies detected and the presence of ADAs did not alter the LDL-Clowering efficacy of alirocumab.
Discussion
This was the first study with alirocumab at the 75-mg dose sc. Q2W utilizing self-injection in a population not receiving statin background therapy and also utilizing an uptitration scheme based on LDL-C response. The results demonstrate alirocumab resulted in a highly effective clinicAl triAl report Roth & McKenney future science group reduction in LDL-C of approximately 50%, as projected from Phase II study results, and also resulted in 70% (32/46) of patients achieving a LDL-C of <70 mg/dl (<1.8 mmol/l) at week 12 from a baseline LDL-C of 141 mg/dl (3.6 mmol/l; 46 patients had a week-12 visit in the study). Furthermore, the study demonstrated that the difference between alirocumab and ezetimibe in lowering LDL-C (47.2 vs 15.6%, respectively, after 24 weeks of treatment in the ITT evaluation) is highly significantly different (p < 0.0001). There were no meaningful differences between alirocumab and ezetimibe in terms of safety parameters. Numerically, more patients receiving alirocumab experienced nasopharyngitis and diarrhea and more had glucose levels above 126 mg/dl (>7 mmol/l) than in those receiving ezetimibe. Again, there was no pattern of change in glucose or HbA1c from screening to week 24 as previously described in the safety section. Ongoing Phase III ODYSSEY studies with much larger numbers of patients will help further document the safety of alirocumab. The group receiving an uptitration of alirocumab to 150 mg sc. Q2W had higher LDL-C baseline levels, as may be expected. Alirocumab levels rose to approximately double the blood concentration and PCSK9 levels declined further. However, LS mean LDL-C levels at week 24 were not appreciably different between the uptitrated and non-uptitrated alirocumab groups. This may have been because the suppression in PCSK9 was already substantial when the dose was increased but some (albeit small) additional reduction would have been expected. In the Phase II dose-ranging study, 100 mg sc. Q2W and 150 mg sc. Q2W resulted in LS mean LDL-C reductions of 64 and 72%, respectively, after 12 weeks of treatment [14] . However, the dose-ranging study was conducted on the background of statin therapy, which is known to increase PCSK9 levels by 35-45%, and this may accentuate the LDL-C lowering www.futuremedicine.com ODYSSEY MONO clinicAl triAl report achieved when the PCSK9 mAb is administered [21] . A doubling of the PCSK9 mAb dose is an approach to enhancing the duration of the LDL-C lowering, especially in patients receiving no background lipid-modifying therapy, as more mAbs would be available to neutralize newly synthesized PCSK9. Based on this consideration, once-monthly administration of the 150-mg alirocumab dose is currently being tested in the ODYSSEY CHOICE II study.
Conclusion
These data suggest that the 75-mg dose of alirocumab sc. Q2W may be appropriate for adequate lowering of LDL-C in a large portion of patients with primary hypercholesterolemia at moderate CV risk who are not receiving statin therapy. In addition, the safety profile continues to show good tolerability and appears comparable to that of ezetimibe in this study. Alirocumab self-injected sc. Q2W appears to be a viable option for lowering LDL-C in patients unable or unwilling to utilize statin therapy. An uptitration plan based on LDL-C response appears to be feasible and may be useful in future clinical practice. Alirocumab significantly lowers LDL-C to a much greater degree than ezetimibe, which is a commonly prescribed lipid-lowering medicine. 
executive summAry

Background
• Alirocumab (formerly SAR236553/REGN727) is a monoclonal antibody directed at PCSK9 that showed good efficacy in Phase II trials when added to background statin therapy.
• This is the first completed Phase III study in the ODYSSEY development program and is unique (compared with the Phase II studies) in the dose used (starting dose of 75 mg), the population (no background lipid-modifying therapies), the use of disposable autoinjectors for self-administration, the length of the study (24 weeks) and the alirocumab uptitration scheme (75-150 mg at week 12) for LDL-cholesterol (LDL-C) >100 mg/dl at week 8.
Study design
• This was a randomized, double-blind, active-controlled (ezetimibe), parallel-group, double-dummy study. General inclusion criteria were LDL-C between 100 and 190 mg/dL on no lipid-lowering medications in a moderate-risk population with a European Systematic Coronary Risk Estimation (SCORE) of 1-4%. In total, 103 patients were randomized into the study.
Data analysis
• The primary efficacy analysis population was the intent-to-treat (ITT) population, defined as the randomized population that actually received at least one dose or partial dose of investigational medicinal product and had both the baseline and at least one subsequent LDL-C value.
results
• The primary end point -the percentage difference (least square mean) in LDL-C between the alirocumab arm and the ezetimibe arm at 24 weeks -was -31.6% for the ITT population (p < 0.0001). LDL-C lowering with alirocumab was 47.2% and with ezetimibe was 15.6%.
clinicAl triAl report Roth • Thirteen patients were uptitrated in error at week 12 from 75 to 150 mg subcutaneously every 2 weeks due to a programming error in the interactive voice responsive system (LDL-C ≥70 mg/dl instead of ≥100 mg/dl per protocol). Uptitration did not result in a significant decrease in LDL-C compared with the non-uptitrated group, and the primary end point excluding the 13 incorrectly uptitrated patients was not significantly different from the ITT population results.
Safety
• Safety parameters, adverse events and study discontinuation rates were similar between the two groups. No patterns of change in glucose or HbA1c were observed from screening to week 24. LDL-C values of <25 mg/dl were not associated with any particular safety finding. Low levels of antidrug antibodies were present in four of the alirocumab patients and these levels decreased or disappeared from week 12 to week 24, and then to week 34 (the follow-up visit).
Significance
• Alirocumab showed significantly better LDL-C lowering than ezetimibe, with a comparable safety profile to ezetimibe. Uptitrated patients did not show a significant reduction in their LDL-C compared with that achieved with alirocumab 75 mg subcutaneously every 2 weeks; this may have occurred because the PCSK9/LDL receptor system was already saturated in these patients.
Conclusion
• This new lower dose of alirocumab may be adequate to achieve substantial LDL-C lowering for many hypercholesterolemic patients at moderate cardiovascular risk who are not receiving other lipid-modifying therapies.
